A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2.

A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics (2001) 15.03

Sialic acid-deficient serum and cerebrospinal fluid transferrin in a newly recognized genetic syndrome. Clin Chim Acta (1984) 1.83

IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer (2014) 1.75

Understanding human glycosylation disorders: biochemistry leads the charge. J Biol Chem (2013) 1.72

The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim Biophys Acta (2009) 1.70

Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A. Am J Hum Genet (1998) 1.66

Functional significance of PMM2 mutations in mildly affected patients with congenital disorders of glycosylation Ia. Genet Med (2001) 1.49

Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Hum Mutat (2000) 1.48

Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts. J Clin Invest (1996) 1.38

Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clin Chem (2001) 1.38

Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia). Eur J Hum Genet (2000) 1.34

Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1. Eur J Hum Genet (1998) 1.22

Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I. Acta Paediatr (1997) 1.20

Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts. J Biol Chem (2011) 1.19

Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H/F119L genotype. Arch Dis Child (2001) 1.16

Targeted disruption of the mouse phosphomannomutase 2 gene causes early embryonic lethality. Mol Cell Biol (2006) 1.15

Screening and diagnosis of congenital disorders of glycosylation. Clin Chim Acta (2007) 1.11

Successful prenatal mannose treatment for congenital disorder of glycosylation-Ia in mice. Nat Med (2011) 1.06

IGF system in children with congenital disorders of glycosylation. Clin Endocrinol (Oxf) (2009) 1.05

PTX3 as a paradigm for the interaction of pentraxins with the complement system. Semin Immunol (2013) 1.04

The immunoglobulin-like module of gp130 is required for signaling by interleukin-6, but not by leukemia inhibitory factor. J Biol Chem (1998) 1.02

Carbohydrate-deficient glycoprotein syndrome type 1A: expression and characterisation of wild type and mutant PMM2 in E. coli. Eur J Hum Genet (1999) 1.02

Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A. Acta Paediatr (1998) 1.01

N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130. J Biol Chem (2009) 0.98

The skeletal manifestations of the congenital disorders of glycosylation. Clin Genet (2008) 0.96

Evidence of a role for insulin-like growth factor binding protein (IGFBP)-3 in metabolic regulation. Endocrinology (2010) 0.93

Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patients. Biochim Biophys Acta (2009) 0.92

Clinical and molecular features of congenital disorder of glycosylation in patients with type 1 sialotransferrin pattern and diverse ethnic origins. J Pediatr (2002) 0.91

Mannose metabolism: more than meets the eye. Biochem Biophys Res Commun (2014) 0.90

The metabolic origins of mannose in glycoproteins. J Biol Chem (2014) 0.89

Congenital disorder of glycosylation type 1a: three siblings with a mild neurological phenotype. J Clin Neurosci (2007) 0.87

Thrombotic complications in patients with PMM2-CDG. Mol Genet Metab (2013) 0.87

Prepubertal growth in congenital disorder of glycosylation type Ia (CDG-Ia). Arch Dis Child (2002) 0.87

A new insight into PMM2 mutations in the French population. Hum Mutat (2005) 0.84

Clinical features in adults with congenital disorders of glycosylation type Ia (CDG-Ia). Am J Med Genet C Semin Med Genet (2007) 0.84

Congenital disorders of glycosylation. Part I. Defects of protein N-glycosylation. Acta Biochim Pol (2013) 0.84

Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation. Mol Genet Genomic Med (2013) 0.83

The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations. JIMD Rep (2011) 0.81

Retinal characteristics of the congenital disorder of glycosylation PMM2-CDG. J Inherit Metab Dis (2013) 0.81

Mannose supplements induce embryonic lethality and blindness in phosphomannose isomerase hypomorphic mice. FASEB J (2014) 0.81

Thyroid function in PMM2-CDG: diagnostic approach and proposed management. Mol Genet Metab (2012) 0.81

Quantification of human serum transferrin using liquid chromatography-tandem mass spectrometry based targeted proteomics. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.78

Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type I. J Inherit Metab Dis (2011) 0.78

Skeletal dysplasia and myelopathy in congenital disorder of glycosylation type IA. J Pediatr (2006) 0.77

Mitotic Intragenic Recombination: A Mechanism of Survival for Several Congenital Disorders of Glycosylation. Am J Hum Genet (2016) 0.75